Company Description
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.
The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers.
The company was founded in 1998 and is headquartered in Andover, Massachusetts.
| Country | United States |
| IPO Date | May 2, 2019 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 584 |
| CEO | Dr. Waleed H. Hassanein M.D. |
Contact Details
Address: 200 Minuteman Road Andover, Massachusetts United States | |
| Website | https://www.transmedics.com |
Stock Details
| Ticker Symbol | TMDX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001756262 |
| CUSIP Number | 89377M109 |
| ISIN Number | US89377M1099 |
| Employer ID | 00-0000000 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Dr. Waleed H. Hassanein M.D. | Founder, President, Chief Executive Officer & Director |
| Gerardo Hernandez | Chief Financial Officer |
| Anil Ranganath | Senior Vice President, General Counsel & Corporate Secretary |
| Dr. Tamer I. Khayal M.D. | Chief Commercial Officer |
| Miriam C. Provost Ph.D. | Vice President of Global Regulatory Affairs |
| Nicholas Corcoran | Senior Vice President of Supply Chain & Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 11, 2024 | 4 | Filing |
| Dec 09, 2024 | 8-K | Current Report |
| Dec 06, 2024 | SCHEDULE 13G/A | [Amend] Filing |
| Dec 04, 2024 | 4 | Filing |
| Dec 02, 2024 | 3 | Filing |
| Dec 02, 2024 | 8-K | Current Report |
| Nov 13, 2024 | 4 | Filing |
| Nov 07, 2024 | 4 | Filing |
| Nov 05, 2024 | 4 | Filing |
| Oct 29, 2024 | 10-Q | Quarterly Report |